Studies of health care costs and resource utilization in patients with inflammatory myopathy in managed health care revealed annual medical costs were higher among newly diagnosed patients and those with existing inflammatory myopathy compared to unaffected controls.1
Some myopathies are more common in the elderly, such as inclusion body myositis and myopathy secondary to cholesterol lowering medication (statin myopathy).
Incidence rates of ALS increase with age, peaking between 70 and 80 years. Amyotrophic lateral sclerosis is a fatal condition for most patients with mean life expectancy of about 3 years after diagnosis, although some patients live longer.
